SAveRUNNER: an R-based tool for drug repurposing

Giulia Fiscon1,2 and Paola Paci1,3*

Background
Currently, we are still facing a global pandemic caused by the new coronavirus SARS-CoV-2. The viral waves in Europe and the United States restarted in August and mid-September are driving the steep upward trend of the global daily tally for new COVID-19 cases that increases up to new high records, suggesting that this wave will be worse than the one that swept the countries over the spring–summer.

Even though mass vaccination campaigns have been started across countries, it remains difficult to achieve herd immunity in a short time and the proportion of the population that...
is susceptible to the new coronavirus is still insufficient for new outbreaks to peter out. To meet the compelling need of finding new therapeutic options devoted to combat SARS-CoV-2 infection [1, 2], promising insights come from drug repurposing, a recent strategy for identifying novel uses for drugs approved by the US Food and Drug Administration (FDA) outside the scope of their original medical indication [3]. Establishing whether an ‘old drug’ can be reused for new therapeutic purposes represents a faster and cheaper alternative to de novo drug discovery, which generally takes 2–3 billion dollars and 12–15 years [3]. Hence, drug repurposing strategy appears as a powerful solution for emerging diseases, such as COVID-19 [4]. In this context, we developed SAveRUNNER (Searching off-lAbel dRUg aNd NEtwoRk), a new network-based tool for drug repurposing that exploits concepts from the emerging field of network medicine [5–9]. According to the new paradigm of Network Medicine, diseases can be interpreted as local perturbations in the human interactome map (i.e., the cellular network of all physical molecular interactions), where the molecular determinants of a given disease (disease genes) are not randomly scattered, but co-localize and agglomerate in specific regions (disease modules) [6, 10]. Perturbations in these disease modules can contribute to pathobiological phenotype manifestation. From this perspective, also the drugs’ action can be interpreted as a local perturbation of the interactome and thus, for a drug to be on-target effective against a specific disease or to cause off-target adverse effects, its target proteins should be within or in the immediate vicinity of the corresponding disease module [11–13]. Inspired by this philosophy, SAveRUNNER predicts drug–disease associations by quantifying the vicinity between the drug targets and the disease-associated proteins in the human interactome via a novel network-based similarity measure that rewards associations between drugs and diseases located in the same network neighborhoods. SAveRUNNER yielded a high accuracy in the identification of well-known drug indications, as well as being able to provide interesting clues regarding off-label prediction of drugs to be repositioned against the new human coronavirus [14].

**Implementation**

SAveRUNNER (Searching off-lAbel dRUg aNd NEtwoRk) is a network-based algorithm for drug repurposing that, taking as input a list of drug targets and disease genes, predicts drug-disease associations by computing a new network-based similarity measure to prioritize associations between drugs and diseases located in the same network neighborhoods by performing the following steps (Fig. 1).

**Computation of network proximity**

SAveRUNNER implements the network-based proximity measure (Eq. 1) to investigate the extent to which disease and drug modules are close in the human interactome [11]:

\[ p(T, S) = \frac{1}{\| T \|} \sum_{t \in T} \sum_{s \in S} \min d(t, s) \]

which is the average shortest path length between drug targets \( t \) in the drug module \( T \) and the nearest disease genes \( s \) in the disease module \( S \).
Computation of z-score proximity and p values

The proximity value between a drug module T and a disease module S was z-score normalized by applying a degree-preserving randomization procedure. In particular, to compute the z-scores and the corresponding p values, SAvERunner builds a reference distance distribution corresponding to the expected distance between two randomly selected groups of proteins with the same size and degree distribution of the original sets of disease proteins and drug targets in the human interactome. This procedure is repeated 1,000 times and the z statistic, together with its p value, is computed by using the mean and the standard deviation of the reference distance distribution. A p value $\leq 0.05$ (corresponding to a $z \leq -1.65$) was expected for a drug and disease module more proximal than expected by chance.

Selection of statistically significant drug-disease associations

In order to filter out statistically insignificant drug-disease associations, a significance level for the p values should be set (typically, $p \text{ value} \leq 0.05$). It means that, given a disease A and a drug b, if the p value associated to their distance in the human interactome
is smaller of the chosen significance level, the probability that the off-label drug \( b \) would be effective for this disease \( \Lambda \) is greater than expected by chance.

**Computation of network similarity**

The network proximity measure \( p \) defined in Eq. 1 is translated in a similarity measure (Eq. 2) assuming values in the range \([0–1]\):

\[
similarity = \frac{\max(p) - p}{\max(p)}
\]  
(2)

Null similarity means that the corresponding disease and drug modules are very distal in the human interactome (i.e., \( p \) is maximum); whereas maximum similarity means that the corresponding disease and drug modules are very proximal in the human interactome (i.e., \( p \) equal to zero).

**Cluster detection**

SAveRUNNER exploits a clustering algorithm based on greedy optimization of the network modularity [15] to detect groups of drugs and diseases in such a way that members in the same group (cluster) are more similar to each other than to those in other groups (clusters). The quality of each cluster is evaluated by SAveRUNNER through the computation of the quality cluster (QC) score (Eq. 3):

\[
QC = \frac{W_{in}}{W_{in} + W_{out} + P}
\]  
(3)

where \( W_{in} \) denotes the total weight of edges within the cluster, \( W_{out} \) denotes the total weight of edges connecting this cluster to the rest of network, and \( P \) is a penalty term which considers the node density within the cluster (i.e., the ratio of network nodes within each cluster).

**Adjustment of network similarity**

SAveRUNNER uses the QC score to reward associations between drugs and diseases belonging to the same cluster, based on the assumption that if a drug and a disease group together is more likely that the drug can be effectively repurposed for that disease. Thus, drug and the disease that are members of the same cluster tend to be “more similar” and this translates into the adjustment for the similarity (Eq. 4):

\[
similarity = (1 + QC) \cdot similarity
\]  
(4)

In this way, if two nodes fall in the same cluster their similarity value increases by a factor proportional to the QC score of the cluster which they belong; otherwise whether two nodes do not fall in the same cluster QC is set to zero and their similarity value does not change.

**Normalization of network similarity**

The similarity measure defined in Eq. 4 was normalized by applying the following sigmoid function (Eq. 5):
where $x$ is the adjusted similarity measure (Eq. 4), $d$ is the sigmoid midpoint (i.e., the value at which the function approaches to 0.5), $c$ is the sigmoid steepness.

Eventually, SAveRUNNER releases a list of predicted/prioritized associations between drugs and diseases as a weighted bipartite drug-disease network, in which one set of nodes corresponds to drugs and the other one corresponds to diseases. A link between a drug and a disease occurs if the corresponding drug targets and disease genes are nearby in the interactome more than expected by chance ($p$ value $\leq 0.05$) and the weight of their interaction corresponds to the adjusted and normalized similarity value.

Results
SAveRUNNER predictions of repurposable drugs in relation to COVID-19
In order to evaluate the effectiveness of predicted drug–disease associations, we applied SAveRUNNER on several human diseases for which original medical indications were available. In particular, given the deep impact of the ongoing COVID-19 pandemic, we selected a panel of 15 disorders, including COVID-19 and 14 diseases related to COVID-19 (SARS-CoV-2) for genetic similarity, comorbidity, or for their association to drugs with ongoing clinical trials for treating COVID-19 patients. We tested Severe Acute Respiratory Syndrome (SARS) since it is caused by the coronavirus with the highest sequence identity with SARS-CoV-2 [12, 16] and there exists a well-established knowledge of its associated disease genes [17]. Moreover, we included also diabetes, cardiovascular diseases, and hypertension, whose comorbidity in COVID-19 patients is well documented [18, 19]; and finally other viral infections (i.e., malaria, HIV and Ebola) and immune disorders (i.e., rheumatoid arthritis), since drugs approved for their treatment are being investigated for their potential effect to fight coronavirus disease [1, 20–27].

COVID-19-associated genes were downloaded from [28], where the authors identified 332 human proteins interacting with 26 SARS-CoV-2 proteins by using affinity purification mass spectrometry. Although this study has been carried out on human HEK293T kidney cells that do not represent the primary physiological site of infection, the authors verified that these proteins were preferentially highly expressed in lung tissue (the typical environment where the virus causes a major damage). Yet, the disease-associated genes for the other selected 14 diseases were downloaded from Phenopedia [17], the drug-target interactions were acquired from DrugBank [29], and the human interactome was retrieved from [11] (Fig. 2 and Additional file 1).

The list of network-predicted drugs potentially able to treat SARS-CoV-2 infection contains a total of 98 drugs (Additional file 2), including 54 (i.e., 55%) COVID-19 specific and 44 (i.e., 45%) in common with the candidate repurposable drugs found for SARS-CoV. The results of this study are broadly discussed in an our recent publication [14]. In Additional file 3, the data analysis details step-by-step were reported via a working example of SAveRUNNER application to COVID-19, from data collection, network, association analysis and predicted repurposable drugs.
SAveRUNNER performance evaluation

The drug–disease associations predicted by the SAveRUNNER was then evaluated in terms of the Receiver Operating Characteristic (ROC) probability curve analysis (Fig. 1). The predicted associations were ranked according to increasing \( p \) values and a “real association” was assigned according to the well-known drug-disease associations downloaded from Therapeutic Target Database (TTD) [30]: 1 corresponds to predicted drug-disease association that is already known, 0 otherwise. For a specified \( p \) value threshold, the true positive rate (i.e., sensitivity) was calculated as the fraction of known associations that are correctly predicted, while the false positive rate (i.e., 1-specificity) was computed as the fraction of unknown associations that are predicted. The ROC probability curve was drawn based on these measures at different thresholds and the corresponding Area Under the Curve (AUC) was computed. The higher the AUC, the better the algorithm is at distinguishing between two classes (i.e., known drug-disease associations vs. unknown drug-disease associations). SAveRUNNER achieved over 70\% accuracy (AUC = 0.73) for identifying well-known drug-disease relationships (Fig. 1), meaning that there is 73\% chance that the SAveRUNNER algorithm will be able to distinguish between positive class (known drug-disease associations) and negative class (unknown drug-disease associations).

Comparison with other methods

Among network-based methods proposed to predict direct drug–disease associations for drug repositioning [3, 31–35], the MBiRW algorithm has been shown to outperform other well-known network-based prediction methods [36–38] in correctly predicting true drug–disease associations. MBiRW adopts an effective mechanism to measure similarity for drugs and diseases and applies a Bi-Random walk (BiRW) algorithm to predict potential new indications for existing drugs [35]. These captivating results prompted us
to implement a BiRW-based algorithm against which we compared the performance of SAveRUNNER. Details of BiRW-based algorithm implementation are provided as Additional file 4.

We evaluated and compared the drug–disease predictions provided by BiRW and SAveRUNNER in terms of ROC probability curves with their corresponding AUC. In particular, we found that SAveRUNNER yielded over 70% accuracy ($AUC = 0.73$) for identifying well-known drug-disease relationships and overcame the one obtained by the BiRW-based algorithm ($AUC = 0.59$). In other words, there is 73% chance that SAveRUNNER algorithm will be able to distinguish between known and unknown drug-disease associations against the 59% of the BiRW-based algorithm (Fig. 3).

To further evaluate the performances of SAveRUNNER, we compared its outcomes with the predictions obtained by a recent study, where the authors integrated several network-based drug repurposing strategies to prioritize 81 promising repurposing candidates against COVID-19 [13]. In particular, they combined three predictive approaches: (1) proximity-based methods that allowed to measure the distance between the viral protein targets and both (i) the targets of approved drugs and (ii) the differentially expressed genes induced by each drug; (2) diffusion-based methods to rank drugs based on the network similarity of their targets to COVID-19 protein targets; (3) machine learning methods relying on artificial intelligence network. These pipelines offered altogether twelve ranked lists that were merged using a rank aggregation algorithm in order to obtain a final list of 81 prioritized repurposable drugs. The overlap between these 81 repurposable drugs and the 98 ones predicted by SAveRUNNER is of 5 drugs, i.e. isoniazid, lopinavir, romidepsin, sulfinpyrazone, tadalafil.

However, although the use of more methodologies can provide more reliable and feasible drug repurposable candidates, the lack of a unified pipeline makes it difficult for non-expert users to exploit this approach for own research purposes.

![Fig. 3 ROC curves for predicting drug–disease associations. The ROC curve is computed for SAveRUNNER algorithm (light blue curve) and BiRW algorithm (orange curve) by plotting the true positive rate (TPR), i.e., sensitivity placed on Y-axis against the false positive rate (FPR), i.e., 1-specificity placed on X-axis at various threshold settings. Diagonal grey line represents the line of no-discrimination between positive class (known drug-disease associations) and negative class (unknown drug-disease associations).](image)
Availability and requirements

Project name: SAveRUNNER.
Project page: https://github.com/giuliascifon/SAveRUNNER.git.
Operating system(s): macOS High Sierra 10.13.6, Windows 10 Pro.
Programming language: R.
Other requirements: R version 3.5.1 or higher.
License: GNU AFFERO GENERAL PUBLIC LICENSE.

Abbreviations
FDA: Food and drug administration; SAveRUNNER: Searching off-lAbel dRUg aNd NEtwoRk; QC: Quality score; AUC: Area under the curve; TTD: Therapeutic target database; ROC: Receiver operating characteristic.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12859-021-04076-w.

Additional file 1. Table composed of three separate sheets. The first sheet reports the analyzed diseases with the corresponding number of disease-causing genes. The second sheet reports the analyzed FDA-approved drugs with the corresponding number of target proteins. The third sheet reports the analyzed diseases with the corresponding number of repurposable drugs predicted by SAveRUNNER.

Additional file 2. List of repurposable drugs for COVID-19 predicted by SAveRUNNER along with their statistics.

Additional file 3. Working example of SAveRUNNER application to COVID-19.

Additional file 4. Implementation of BiRW-based algorithm for drug repurposing.

Acknowledgements
Not applicable.

Authors’ contributions
PP conceived and designed the research. PP and GF developed the algorithm and wrote the manuscript. All authors have read and approved the manuscript.

Funding
This work was financially supported by PRIN 2017—Settore ERC LS2—Codice Progetto 20178L3P38. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials
All data generated or analyzed during this study are included in this published article. SAveRUNNER code is open-source and it is available at https://github.com/giuliascifon/SAveRUNNER.git, together with an exhaustive and well-documented user guide, which includes a detailed description of all R scripts, all input/output files through a working example of SAveRUNNER application on 15 diseases, including COVID-19.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Institute for Systems Analysis and Computer Science, Antonio Ruberti”, National Research Council, Rome, Italy.
2 Fondazione Per La Medicina Personalizzata, Via Goffredo Mameli, 3/1, Genoa, Italy. 3 Department of Computer, Control and Management Engineering, Sapienza University of Rome, Rome, Italy.

Received: 7 December 2020   Accepted: 15 March 2021
Published online: 23 March 2021
References

1. Cao B, et al. A trial of Lopinavir-Ritonavir in adults hospitalized with severe covid-19. N Engl J Med. 2020;382:1787–99.
2. Borba MGS, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open. 2020;3:e200887–e200887.
3. Pushpakom S, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18:41–58.
4. Zhou Y, Wang F, Tang J, Nussinov R, Cheng F. Artificial intelligence in COVID-19 drug repurposing. Lancet Digit Health. 2020;2:e667–676.
5. Sonawane AR, Weiss ST, Glass K, Sharma A. Network medicine in the age of biomedical big data. Front Genet. 2019;10:294.
6. Barabási A-L, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet. 2011;12:56–68.
7. Silverman EK, et al. Molecular networks in network medicine: development and applications. WIREs Syst Biol Med. 2020;12:e1489.
8. Paci F, et al. Gene co-expression in the interactome: moving from correlation toward causation via an integrated approach to disease module discovery. NPJ Syst Biol Appl. 2021;7:1–11.
9. Conte F, et al. A paradigm shift in medicine: a comprehensive review of network-based approaches. Biochem Biophys Acta BBA Gene Regul Mech. 2020;1863:194416.
10. Caldera M, Buphamalai P, Müller F, Menche J. Interactome-based approaches to human disease. Curr Opin Syst Biol. 2017;3:88–94.
11. Cheng F, et al. Network-based approach to prediction and population-based validation of in silico drug repurposing. Nat Commun. 2018;9:2691.
12. Zhou Y, et al. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 2020;6:1–18.
13. Gysi, D. M. et al. Network Medicine Framework for Identifying Drug Repurposing Opportunities for COVID-19. ArXiv200407229 Cs Q-Bio Stat (2020).
14. Fiscon G, Conte F, Farina L, Paci P. SaveRUNNER: a network-based algorithm for drug repurposing and its application to COVID-19. PLOS Comput Biol. 2021;17:e1008686.
15. Clauset A, Newman MEJ, Moore C. Finding community structure in very large networks. Phys Rev E. 2004;70:066111.
16. Lu R, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–74.
17. Yu W, Clyne M, Khoury MJ, Gwinn M. Phenopedia and Genopedia: disease-centered and gene-centered views of the evolving knowledge of human genetic associations. Bioinformatics. 2010;26:145–6.
18. Chen N, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–13.
19. Wang D, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020. https://doi.org/10.1001/jama.2020.1585.
20. COVID-19: Finding the Right Fit. DrugBank Blog https://blog.drugbankplus.com/data-driven-approaches-to-identify-potential-covid-19-therapies/ (2020).
21. Liu J, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:1–4.
22. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14:72–3.
23. Colson P, Rolain J-M, Lagier J-C, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020. https://doi.org/10.1016/j.ijantimicag.2020.105932.
24. McCarty MF, DiNicolaontio JJ. Nutraceuticals have potential for boosting the type 1 interferon response to RNA viruses including influenza and coronavirus. Prog Cardiovasc Dis. 2020. https://doi.org/10.1016/j.pcad.2020.02.007.
25. Hensley LE, et al. Interferon-β 1a and SARS coronavirus replication. Emerg Infect Dis. 2004;10:317–2.
26. Sahin AR, et al. 2019 novel coronavirus (COVID-19) outbreak: a review of the current literature. Eur J Med Oncol. 2020;4:1–7.
27. Wang M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–71.
28. Gordon DE, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020. https://doi.org/10.1038/s41586-020-2286-9.
29. Wishart DS, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucl Acids Res. 2018;46:D1074.
30. Wang Y, et al. Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics. Nucl Acids Res. 2020;48:D1031–41.
31. Alonso S, Pulivirenti A. Network-based drug repositioning: approaches, resources, and research directions. In: Vanhaelen Q, editor. Computational methods for drug repurposing. New York: Springer; 2019. p. 97–113. https://doi.org/10.1007/978-1-4939-8995-3_6.
32. Loifi Shaheez M, Gladini N, Mousavi SR, Varshosaz J, Green JR. A review of network-based approaches to drug repositioning. Brief Bioinform. 2017;19:878–92.
33. Li J, et al. A survey of current trends in computational drug repositioning. Brief Bioinform. 2016;17:2–12.
34. Xue H, Li J, Xie H, Wang Y. Review of drug repositioning approaches and resources. Int J Biol Sci. 2018;14:1232–44.
35. Luo H, et al. Drug repositioning based on comprehensive similarity measures and Bi-Random walk algorithm. Bioinformatics. 2016;32:2664–71.
36. Cheng F, et al. Prediction of drug-target interactions and drug repositioning via network-based inference. PLOS Comput Biol. 2012;8:e1002503.
37. Wang W, Yang S, Li J. Drug target predictions based on heterogeneous graph inference. Pac Symp Biocomput Pac Symp Biocomput. 2013;2013:53–64.
38. Martínez V, Navarro C, Cano C, Fajardo W, Blanco A. DrugNet: network-based drug-disease prioritization by integrating heterogeneous data. Artif Intell Med. 2015;63:41–9.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.